Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …

Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …

Treatment failure for the lethal brain tumor glioblastoma (GBM) is attributed to intratumoral
heterogeneity and tumor evolution. We utilized 3D neuronavigation during surgical resection …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

The recent boom in microfluidics and combinatorial indexing strategies, combined with low
sequencing costs, has empowered single-cell sequencing technology. Thousands—or even …

A high tumour mutational burden (hypermutation) is observed in some gliomas,,,–; however,
the mechanisms by which hypermutation develops and whether it predicts the response to …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet,
seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of …

Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …